Comparison of clinical effects between granisetron alone and combination of granisetron and methylprednisolone against the nausea and vomiting induced by CDDP chemotherapy comparative study by the cross-over trial

K. Uchida, H. Akaza, T. Shimazui, K. Kikuchi, F. Manabe, A. Iwasaki, S. Ishikawa, R. Noguchi, M. Otani, K. Hattori, F. Kondo, Y. Nishijima, K. Sato, K. Koiso, S. Hinotsu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A cross over clinical trial was carried out to compare the antiemetic effort and safety between granisetron alone (40 μg/kg) and the combination of granisetron and methylprednisolone (MP: 10 mg/kg) in urological cancer patients treated with cisplatin. Forty-eight courses were given with granisetron alone and 47 courses with both granisetron and MP. The antiemetic effect of nausea and vomiting was evaluated in the acute emetic phase, during the 24 hours following the CDDP administration, and in the delayed emetic phase, 2 to 7 days after the administration. Combination therapy of granisetron and MP demonstrated a greatest antiemetic effect during the 72 hours following the CDDP administration than by granisetron alone. But there was no significant difference in antiemetic effect between combination therapy and granisetron alone after the 3rd day. Combination therapy also demonstrated more efficacy in complete antiemetic effect, with no emesis and less than moderate nausea, than by granisetron alone. Both treatments showed no side effects and were safe.

Original languageEnglish
Pages (from-to)81-86
Number of pages6
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume23
Issue number1
Publication statusPublished - 1996
Externally publishedYes

Fingerprint

Granisetron
Methylprednisolone
Cross-Over Studies
Nausea
Vomiting
Antiemetics
Drug Therapy
Emetics
Urologic Neoplasms
Therapeutics
Cisplatin
Clinical Trials
Safety

Keywords

  • CDDP
  • Granisetron
  • Methylprednisolone

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Comparison of clinical effects between granisetron alone and combination of granisetron and methylprednisolone against the nausea and vomiting induced by CDDP chemotherapy comparative study by the cross-over trial. / Uchida, K.; Akaza, H.; Shimazui, T.; Kikuchi, K.; Manabe, F.; Iwasaki, A.; Ishikawa, S.; Noguchi, R.; Otani, M.; Hattori, K.; Kondo, F.; Nishijima, Y.; Sato, K.; Koiso, K.; Hinotsu, S.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 23, No. 1, 1996, p. 81-86.

Research output: Contribution to journalArticle

Uchida, K, Akaza, H, Shimazui, T, Kikuchi, K, Manabe, F, Iwasaki, A, Ishikawa, S, Noguchi, R, Otani, M, Hattori, K, Kondo, F, Nishijima, Y, Sato, K, Koiso, K & Hinotsu, S 1996, 'Comparison of clinical effects between granisetron alone and combination of granisetron and methylprednisolone against the nausea and vomiting induced by CDDP chemotherapy comparative study by the cross-over trial', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 23, no. 1, pp. 81-86.
Uchida, K. ; Akaza, H. ; Shimazui, T. ; Kikuchi, K. ; Manabe, F. ; Iwasaki, A. ; Ishikawa, S. ; Noguchi, R. ; Otani, M. ; Hattori, K. ; Kondo, F. ; Nishijima, Y. ; Sato, K. ; Koiso, K. ; Hinotsu, S. / Comparison of clinical effects between granisetron alone and combination of granisetron and methylprednisolone against the nausea and vomiting induced by CDDP chemotherapy comparative study by the cross-over trial. In: Gan to kagaku ryoho. Cancer & chemotherapy. 1996 ; Vol. 23, No. 1. pp. 81-86.
@article{42362cbabbdf4d429e6dac6cbf49710f,
title = "Comparison of clinical effects between granisetron alone and combination of granisetron and methylprednisolone against the nausea and vomiting induced by CDDP chemotherapy comparative study by the cross-over trial",
abstract = "A cross over clinical trial was carried out to compare the antiemetic effort and safety between granisetron alone (40 μg/kg) and the combination of granisetron and methylprednisolone (MP: 10 mg/kg) in urological cancer patients treated with cisplatin. Forty-eight courses were given with granisetron alone and 47 courses with both granisetron and MP. The antiemetic effect of nausea and vomiting was evaluated in the acute emetic phase, during the 24 hours following the CDDP administration, and in the delayed emetic phase, 2 to 7 days after the administration. Combination therapy of granisetron and MP demonstrated a greatest antiemetic effect during the 72 hours following the CDDP administration than by granisetron alone. But there was no significant difference in antiemetic effect between combination therapy and granisetron alone after the 3rd day. Combination therapy also demonstrated more efficacy in complete antiemetic effect, with no emesis and less than moderate nausea, than by granisetron alone. Both treatments showed no side effects and were safe.",
keywords = "CDDP, Granisetron, Methylprednisolone",
author = "K. Uchida and H. Akaza and T. Shimazui and K. Kikuchi and F. Manabe and A. Iwasaki and S. Ishikawa and R. Noguchi and M. Otani and K. Hattori and F. Kondo and Y. Nishijima and K. Sato and K. Koiso and S. Hinotsu",
year = "1996",
language = "English",
volume = "23",
pages = "81--86",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "1",

}

TY - JOUR

T1 - Comparison of clinical effects between granisetron alone and combination of granisetron and methylprednisolone against the nausea and vomiting induced by CDDP chemotherapy comparative study by the cross-over trial

AU - Uchida, K.

AU - Akaza, H.

AU - Shimazui, T.

AU - Kikuchi, K.

AU - Manabe, F.

AU - Iwasaki, A.

AU - Ishikawa, S.

AU - Noguchi, R.

AU - Otani, M.

AU - Hattori, K.

AU - Kondo, F.

AU - Nishijima, Y.

AU - Sato, K.

AU - Koiso, K.

AU - Hinotsu, S.

PY - 1996

Y1 - 1996

N2 - A cross over clinical trial was carried out to compare the antiemetic effort and safety between granisetron alone (40 μg/kg) and the combination of granisetron and methylprednisolone (MP: 10 mg/kg) in urological cancer patients treated with cisplatin. Forty-eight courses were given with granisetron alone and 47 courses with both granisetron and MP. The antiemetic effect of nausea and vomiting was evaluated in the acute emetic phase, during the 24 hours following the CDDP administration, and in the delayed emetic phase, 2 to 7 days after the administration. Combination therapy of granisetron and MP demonstrated a greatest antiemetic effect during the 72 hours following the CDDP administration than by granisetron alone. But there was no significant difference in antiemetic effect between combination therapy and granisetron alone after the 3rd day. Combination therapy also demonstrated more efficacy in complete antiemetic effect, with no emesis and less than moderate nausea, than by granisetron alone. Both treatments showed no side effects and were safe.

AB - A cross over clinical trial was carried out to compare the antiemetic effort and safety between granisetron alone (40 μg/kg) and the combination of granisetron and methylprednisolone (MP: 10 mg/kg) in urological cancer patients treated with cisplatin. Forty-eight courses were given with granisetron alone and 47 courses with both granisetron and MP. The antiemetic effect of nausea and vomiting was evaluated in the acute emetic phase, during the 24 hours following the CDDP administration, and in the delayed emetic phase, 2 to 7 days after the administration. Combination therapy of granisetron and MP demonstrated a greatest antiemetic effect during the 72 hours following the CDDP administration than by granisetron alone. But there was no significant difference in antiemetic effect between combination therapy and granisetron alone after the 3rd day. Combination therapy also demonstrated more efficacy in complete antiemetic effect, with no emesis and less than moderate nausea, than by granisetron alone. Both treatments showed no side effects and were safe.

KW - CDDP

KW - Granisetron

KW - Methylprednisolone

UR - http://www.scopus.com/inward/record.url?scp=9044228025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044228025&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 81

EP - 86

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 1

ER -